10x Genomics (TXG) Free Cash Flow (2018 - 2026)

10x Genomics has disclosed Free Cash Flow across 9 years of filings, most recently posting $15.4 million for Q2 2026.

• In Q2 2026, Free Cash Flow fell 4.61% year-over-year to $15.4 million; the TTM figure through Jun 2026 stood at $121.4 million (up 113.51% YoY), while the FY2025 annual figure was $130.1 million, up 2371.16% from the prior year.
• Free Cash Flow came in at $15.4 million for Q2 2026 at 10x Genomics, down from $24.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $42.5 million in Q3 2025 to a low of -$48.9 million in Q1 2022.
• Average Free Cash Flow over 5 years is -$3.6 million, with a median of -$2.4 million recorded in 2024.
• Year-over-year, Free Cash Flow tumbled 285.94% in 2022 and jumped 512.09% in 2025.
• Over 5 years, Free Cash Flow stood at -$26.0 million in 2022, then soared by 185.76% to $22.3 million in 2023, then tumbled by 142.42% to -$9.5 million in 2024, then jumped by 512.09% to $39.0 million in 2025, then slumped by 60.55% to $15.4 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $15.4 million in Q2 2026, $24.5 million in Q1 2026, and $39.0 million in Q4 2025.